Abcam, ab258782, Human ANXA11 (Annexin-11) knockout HEK-293T cell lysate

Size: 1Kit
ANXA11 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon5.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon5.

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-ANXA11, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Annexin-11 also known as ANXA11 or annexin A11 is a calcium-dependent phospholipid-binding protein with a molecular mass of approximately 56 kDa. It belongs to the annexin family and functions through interactions with membrane phospholipids in a calcium-dependent manner. Annexin A11 is expressed in various tissues including the brain liver and spleen. Molecularly annexin A11 participates in vesicle trafficking endocytosis and the regulation of cell division by interacting with the mitotic spindle apparatus.
Biological function summary
Annexin A11 plays a significant role in cellular processes such as membrane repair cell migration and apoptosis. It does not form a stable part of a large protein complex under normal conditions but interacts dynamically with other proteins during cellular events. This protein influences intracellular calcium signaling which is important for maintaining cellular homeostasis and responding to extracellular stimuli. Annexin A11 regulates actin cytoskeletal organization impacting cell motility and structural integrity.
Pathways
Annexin A11’s functions integrate into critical cell signaling and communication pathways such as the calcium signaling pathway and apoptosis pathway. Within these pathways annexin A11 interacts with other proteins like annexin V and annexin II modifying intracellular responses to calcium fluctuations and apoptotic signals. These pathways ensure proper cellular responses to environmental changes and stress conditions facilitating processes like cell survival and programmed cell death.
Annexin A11 associates with amyotrophic lateral sclerosis (ALS) and certain types of cancer. Mutations in the ANXA11 gene correlate with the development of familial ALS where annexin A11 dysfunction affects neuronal survival and leads to motor neuron degeneration. In certain cancers elevated levels of annexin A11 may influence tumor growth through its role in cell proliferation pathways. In both ALS and cancer proteins such as SOD1 in ALS and cyclin D1 in cancer may have connections to annexin A11’s function and regulatory networks.